Archivos de Medicina

  • ISSN: 1698-9465
  • Journal h-index: 27
  • Journal CiteScore: 11.20
  • Journal Impact Factor: 8.24
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
+44 7460731551
Awards Nomination
Indexed In
  • Genamics JournalSeek
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • Scimago
  • Electronic Journals Library
  • Directory of Research Journal Indexing (DRJI)
  • OCLC- WorldCat
  • Proquest Summons
  • University Grants Commission
  • Geneva Foundation for Medical Education and Research
  • Google Scholar
  • Secret Search Engine Labs
Share This Page


Síndromes Mieloproliferativos Cronicos JAK2 Positivo: Revision Narrativa de la Literatura

Oscar Vergara-Serpa, Johan Conquett-Huertas, Nehomar Pájaro-Galvis, Diana Zapata-Cerpa; Oscar Echenique-Torres, Jorge Rico-Fontalvo,  Víctor Leal-Martínez, Rodrigo Daza-Arnedo, Lácides Caparroso-Ramos and Christian Pérez-Calvo

Introduction: Chronic myeloproliferative syndromes (CMS) JAK2+, classified as polycythemia vera (PV), essential thrombocytosis (ET) and primary myelofibrosis (PMF) are disorders derived stem cells. Mutations in the gene januskinase-2 (JAK-2) is characteristic of these diseases. It is estimated that each has a rate of 0.5 to 2.5 per 100,000 people per year.

Objective: To evaluate the epidemiological, clinical, diagnosis and treatment characteristics of chronic myeloproliferative neoplasms; in addition, the prevalence and clinical significance of the JAK2 mutation. Methodology: systematic search of the literature using MeSH keywords. Chronic myeloid leukemia (CML) was excluded from this review, because its diagnosis is made with the appearance of the Philadelphia chromosome and not by means of a JAK2 mutation.

Results and discussion: SMC are characterized by increased proliferation of red blood cells, white blood cells and platelets, and therefore increase the risk of mortality. They are the demonstrable pathologies with JAK2 mutation for their diagnosis: strong (PV), moderately or weakly (ET, PMF).

Conclusion: The clinical manifestations of these entities overlap, as do their genetic drivers, and they are capable of evolving into another type, which makes diagnosis difficult. It is important to evaluate the presence of the JAK2 mutation in patients with CMS.